Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing, and Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies.
Abstract
Background
AND
Objective
Tyrosine kinase inhibitors (TKIs) are targeted cancer therapies. However, TKIs are still limited due to their high inter-individual variability. This study evaluated target attainment using therapeutic drug monitoring (TDM) data from 12 TKIs, and investigated biochemical and patient-related characteristics influencing TKI pharmacokinetics (PK)
Methods
This single-centre retrospective study included cancer patients treated with TKIs between January 2020 and August 2024. Demographic, clinical, and biochemical data were extracted from electronic health records. Univariate and multivariate linear mixed models were used to identify factors associated with TKI PK.
Results
A total of 1237 TKI concentrations from 309 patients were included. Target attainment percentages were: 74.6% for alectinib; 70% for bosutinib; 49.9-61.9% for imatinib depending on the indication; 88.9% for nilotinib; 50% for pazopanib; 50% for ponatinib; 89.5% for regorafenib; 26.6% for sunitinib; ibrutinib, lenvatinib and trametinib had too few data for formal assessment; 40-87.5% for dasatinib, depending on indication and parameter (Cmax or Cmin). A mixed linear model analysis identified key parameters correlated with TKI concentrations. Glomerular filtration rate was correlated with alectinib, imatinib, and sunitinib. Alkaline phosphatase (ALP), bilirubin, and Gamma-GT correlated with alectinib and ALP with imatinib. Albumin and thrombocytes correlated with imatinib, thrombocytes with pazopanib, absolute neutrophiles count (ANC) with ponatinib, and haematocrit with regorafenib.
Conclusion
Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing. Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies.
Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, J. Bos et al.· Basic & Clinical Pharmacolog...· 0 citations
Tyrosine kinase inhibitors (TKIs) are widely used across multiple malignancies, but treatment-related toxicities remain a major cause of healthcare utilization and treatment modification. Serum albumin is a routinely available biomarker that reflects nutritional status, systemic inflammation, and physiologic vuln...
Ahmed S. Alanazi, Mohammed A. Alnuhait, Norah M. Almutairi et al.· BMC Cancer· 0 citations
Simulations suggest that lower lorlatinib doses may be feasible and MIPD may reduce toxicity, underscoring the importance of external validation of clinical trial-derived models.
L. Bukkems, Benoit Blanchet, J. Arrondeau et al.· Clinical Pharmacokinetics· 0 citations
Cabozantinib is a small‐molecule tyrosine kinase inhibitor approved for the treatment of various locally advanced or metastatic solid tumors. The phase 1b COSMIC‐021 study evaluated cabozantinib as a monotherapy or in combination with atezolizumab in patients with advanced solid tumors, including castration‐resistant p...
Jason H. Williams, Han-Bin Li, A. Othman· Clinical and Translational S...· 0 citations
Global trials are geographically and developmentally unbalanced, with incomplete public availability of trial results, and future research should strengthen international collaboration, optimize trial phase distribution, support novel agent development, and promote timely and complete public disclosure of trial results...
Li-Chuan Zhang, Qi Tian, Ya-Lin Tang et al.· Frontiers in Pharmacology· 0 citations
OBJECTIVE
Beta-lactam therapeutic drug monitoring (BL-TDM) is underused in pediatric patients where drug exposure is highly variable. This study evaluated the pharmacokinetic/pharmacodynamic (PK/PD) target attainment of BLs in pediatrics.
PATIENTS AND METHODS
A retrospective observational cohort study of BL-TDM was c...
V. Venugopalan, K. Manasco, Ahmad Hachem et al.· Hospital Pediatrics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.